Therapeutic Advances in Childhood Leukemia (TACL)

IPCR has formed the Therapeutic Advances in Childhood Leukemia (TACL) clinical trial consortium of pediatric cancer centers to carry out initial clinical trials of new drugs and new drug combinations in childhood leukemia.

Drugs to be tested in the TACL consortia come from CHLA and from the pharmaceutical industry. TACL consists of carefully selected academic institutions located across the USA, Canada, Australia, and Brazil. Ongoing laboratory research on the drugs and studies of drug effects on children will be an integral part of IPCR. Drugs that prove promising in early clinical trials will be brought to the attention of the national cooperative group for childhood cancer, the Children's Oncology Group (COG), and IPCR investigators will work closely with the COG to design and carry out the large, nationwide trials needed to determine the ultimate value of the new drug (or drug combination) in treating a given childhood cancer.

> Go to TACL website